Viibryd (Vilazodone): A Guide to Its Use for Depression and Anxiety

Viibryd (vilazodone) is an FDA-approved medication for treating major depressive disorder (MDD) in adults, known for its faster action compared to many other antidepressants. This handout provides an overview of Viibryd, including its benefits, dosing guidelines, potential side effects, contraindications, and off-label uses supported by research.

Benefits for Depression and Anxiety

Major Depressive Disorder (MDD)

In clinical studies, Viibryd has been shown to effectively ease symptoms of depression. Patients taking Viibryd experienced a reduction in depression symptoms as measured by the Montgomery-Asberg Depression Rating Scale (MADRS), with scores between 2.5 to 5.1 points lower than those taking a placebo[1].

Generalized Anxiety Disorder (GAD) - Off-label Use

Although not FDA-approved for this use, Viibryd has been studied for treating generalized anxiety disorder (GAD). Research indicates that Viibryd can be beneficial for patients with GAD, showing improvement in anxiety symptoms[4].

Dosing Guidelines

Viibryd should be taken once daily with food to enhance absorption. It is available in 10 mg, 20 mg, and 40 mg tablets. The usual starting dose is 10 mg once daily for 7 days, increased to 20 mg once daily, and then to 40 mg once daily as tolerated[1][2].

Best Time to Take

It is recommended to take Viibryd at the same time each day to maintain an even level of the medication in your body. Taking it with food can help increase its absorption[2].

Potential Side Effects

Common side effects of Viibryd include[1][2][5]:

• Diarrhea

• Nausea

• Vomiting

• Insomnia

Serious side effects can include:

• Serotonin syndrome: Symptoms include hallucinations, confusion, racing heartbeat, and changes in blood pressure[1]. This occurs when taken with other medications or supplements that increase serotonin. 

• Discontinuation syndrome: Symptoms include flu-like symptoms, anxiety, insomnia, and mood changes if the medication is stopped abruptly[1].

• Increased risk of suicidal thoughts and behaviors in people 24 years of age and younger[1][3].

Potential Contraindications

Do not take Viibryd if you:

• Are taking or have taken a monoamine oxidase inhibitor (MAOI) within 14 days[3].

• Are being treated with the antibiotic linezolid or intravenous methylene blue[3].

FDA Approval Information

Viibryd was approved by the FDA for the treatment of major depressive disorder (MDD) in adults. It is not approved for use in children[1][3].

Off-label Benefits Supported by Research

In addition to its use for MDD, Viibryd has shown promise in treating generalized anxiety disorder (GAD) in off-label studies. These studies suggest that Viibryd can improve symptoms of anxiety in patients with GAD[4].

For more detailed information about Viibryd, including its full list of side effects, interactions, and more, consult your healthcare provider.